Le Lézard
Classified in: Business
Subject: LAW

Notice from the Office of the Secretary - Ontario Securities Commission


1832 ASSET MANAGEMENT L.P., File No.2018-20

TORONTO, April 19, 2018 /CNW/ - The Office of the Secretary issued a Notice of Hearing for a hearing to consider whether it is in the public interest to approve a settlement agreement entered into by Staff of the Commission and 1832 Asset Management L.P. in the above named matter.

The hearing will be held on April 24, 2018 at 9:00 a.m. on the 17th floor of the Commission's offices located at 20 Queen Street West, Toronto.

A copy of the Notice of Hearing dated April 19, 2018 and Statement of Allegations dated April 19, 2018 are available at www.osc.gov.on.ca

OFFICE OF THE SECRETARY
GRACE KNAKOWSKI
SECRETARY TO THE COMMISSION

SOURCE Ontario Securities Commission


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 20:39
Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...

at 20:15
The partnership was unveiled internally at the Franchisor's annual convention in Las Vegas, NV in December 2023, eliciting...

at 19:35
Regenx Tech Corp., (the "Company" or "Regenx") is providing this bi-weekly update on the status of the application to the Alberta Securities Commission for a management cease trade order, under National Policy 12-203 -?? Management Cease Trade...

at 19:14
Kadestone Capital Corp. ("Kadestone" or the "Company") , a vertically integrated property company today announced its financial results for the year ended December 31, 2023....

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...



News published on and distributed by: